PARPi showed improvement in tumor drug response, OS and PFS for patients with locally advanced or metastatic HER2-negative BC with BRCA1/2 germline variation [158], thus supporting the use of PARPi in BC patient care. This evidence concerns the gene BRCA1 and neoplasm.